KIR3DL1 and B-cell chronic lymphocytic leukemia: Thus, a priori, this variability could be partly explained by (i) the degree of HLA–KIR mismatch between donor and patient as found in AML and ALL or (ii) the intrinsic resistance of cells from some B-CLL patients to activated NK cells.